Fig. 2: Schematic representation of the ViroTreat algorithm.

a Virus-induced MR proteins—the Viral Checkpoint—dissected by VIPER analysis of a gene expression signature, obtained by comparing an infected tissue or relevant model with non-infected mock controls. b Context-specific drug MoA database, generated by perturbing an appropriate cell model with therapeutically relevant drug concentrations, followed by VIPER analysis of the drug-induced gene expression signatures to infer the drug-induced protein activity signature. ViroTreat prioritizes drugs able to activate the Viral Checkpoint’s negative MR proteins by quantifying the enrichment of such proteins on the drugs’ context-specific MoA.